After a dreadful 2016, biotech stocks have rebounded nicely this year for a variety of reasons. Most importantly, though, the specter of government-mandated price caps on specialty medicines appears to have faded into the background -- at least for the time being.
So, to take advantage of this more favorable climate, we asked three of our contributors which biotech stocks they think are worth buying in May. They suggested Galapagos NV, Insys Therapeutics, and Portola Pharmaceuticals. Here’s why.
